Sydney, Australia (ABN Newswire) – Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has signed a contract to build a new Research & Development (“R&D”) centre in the Zhuhai National High-Tech Industrial Development Zone in China. Beroni aspires to build a state-ofthe-art facility with new preclinical research labs, manufacturing process development labs, and a GMP pilot manufacturing plant.
The new R&D centre — the first R&D site for Beroni — will help the Company develop new drugs and medicines to cater for the vast needs of the Chinese market. To start with, the Company will occupy about 4,000 square metres (44,000 square feet) of office space for setting up the GMP plant and laboratories. Construction of the new R&D facilities is expected to be completed towards the end of the second quarter, and the entire R&D centre is expected to be ready in the second half of this year. Beroni intends to commit US$10 million to support the clinical trials in the new R&D facility. A new company, Beroni Pharmaceutical (Guangdong) Co., Ltd, has been established for this new venture with Beroni owning 80% of the entity’s shares and a local investor owning the other 20% shares. The Company will bring professional staff, scientists, technicians, and support teams together into a state-of-the-art hub for innovation and development of the company’s future products and services.
Beroni has a drug development pipeline focusing on oncology and immunotherapy. It is moving ahead with the Phase II clinical trial of the anti-cancer molecular drug, PENAO later this year and is scheduled to commence the clinical trials for a few cellular therapies including gamma delta T cell, DC vaccine, and protein modifier R8. It is also currently studying the use of single-domain antibodies for treatment of coronavirus diseases.
“Establishing a new R&D centre in Zhuhai will allow us to expand our R&D capabilities and accelerate our innovative pipeline,” said CEO Jacky Zhang. “In the future, we plan to establish additional R&D centres around the world to advance the discovery and development of new innovative product candidates.”
The Zhuhai National High-Tech Industrial Development Zone Valley, established in 1992, is one of the top biotech hubs in China and is home to hundreds of innovative biotechnology and biopharmaceutical companies. It covers an area of 139 square kilometres and boasts a convenient transportation network with the Beijing-Zhuhai Expressway, Western Guangdong Coastal Expressway and Guangzhou-Zhuhai Intercity MRT passing through the area. Ideally placed for business opportunities, the zone has the location advantage of being within the “One-Hour Economic Circle” of the Pearl River Delta.
About Beroni Group Limited:
Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.
Source:
Beroni Group Limited
Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: [email protected]